No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
INBS Intelligent Bio Solutions
- 1.890
- -0.040-2.07%
Close Jun 18 16:00 ET
5.89MMarket Cap-63P/E (TTM)
2.050High1.880Low27.91KVolume2.020Open1.930Pre Close53.75KTurnover0.97%Turnover RatioLossP/E (Static)3.12MShares39.48052wk High0.53P/B5.44MFloat Cap1.81052wk Low--Dividend TTM2.88MShs Float3417.576Historical High--Div YieldTTM8.81%Amplitude1.810Historical Low1.925Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
When Will Intelligent Bio Solutions Inc. (NASDAQ:INBS) Become Profitable?
Express News | Intelligent Bio Solutions To Begin Subject Dosing And Sampling For FDA 510(k) Pharmacokinetic Study
Express News | Intelligent Bio Solutions Inc - Aims to Complete Dosing by End of June 2024
Express News | Intelligent Bio Solutions Inc - Inbs Plans 510(K) FDA Submission in Q4
Express News | Intelligent Bio Solutions Begins Subject Dosing and Sampling for FDA 510(K) Pharmacokinetic (Pk) Study for Its Intelligent Fingerprinting Drug Screening Technology
Intelligent Bio Solutions Begins Subject Dosing and Sampling for FDA 510(k) Pharmacokinetic (PK) Study for Its Intelligent Fingerprinting Drug Screening Technology
Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it is entering the next phase of its planned 510(k) submission to the FDA.
Comments
$Intelligent Bio Solutions(INBS.US$ Reuters· just
Intelligent Bio Solutions Begins Subject Dosing and Sampling for FDA 510(K) Pharmacokinetic (Pk) Study for Its Intelligent Fingerprinting Drug Screening Technology
Intelligent Bio Solutions Begins Subject Dosing and Sampling for FDA 510(K) Pharmacokinetic (Pk) Study for Its Intelligent Fingerprinting Drug Screening Technology
1
$Intelligent Bio Solutions(INBS.US$
Intelligent Bio Solutions Adds Major European Transport and Infrastructure Solutions Provider to Growing Number of Accounts Adopting Fingerprint Drug Screening Technology
Intelligent Bio Solutions Adds Major European Transport and Infrastructure Solutions Provider to Growing Number of Accounts Adopting Fingerprint Drug Screening Technology
1
$Intelligent Bio Solutions(INBS.US$
Intelligent Bio Solutions Successfully Completes Recruitment and Begins Subject Screening for FDA 510(k) Pharmacokinetic (PK) Study
Intelligent Bio Solutions (Nasdaq: INBS) has successfully recruited subjects and begun screening for its pharmacokinetic (PK) study, a important step in obtaining FDA 510(k) clearance. This study will enhance the understanding of opiate metabolism, distribution, and excretion in human sweat by comparing results from fingerpri...
Intelligent Bio Solutions Successfully Completes Recruitment and Begins Subject Screening for FDA 510(k) Pharmacokinetic (PK) Study
Intelligent Bio Solutions (Nasdaq: INBS) has successfully recruited subjects and begun screening for its pharmacokinetic (PK) study, a important step in obtaining FDA 510(k) clearance. This study will enhance the understanding of opiate metabolism, distribution, and excretion in human sweat by comparing results from fingerpri...
1
$Intelligent Bio Solutions(INBS.US$ Intelligent Bio Solutions Unveils Key Performance Indicator Growth in the United Kingdom as Drug Screening Industry Combats Drug Test Cheating and Searches for Simpler, Faster, Non-Invasive and More Cost-Effective Solutions
2 MINUTES AGO, 8:30 AM EDT
VIA GLOBENEWSWIRE
2 MINUTES AGO, 8:30 AM EDT
VIA GLOBENEWSWIRE
1
$Intelligent Bio Solutions(INBS.US$ Press Release: Intelligent Bio Solutions Inc. Reports Fiscal 2024 Third Quarter and Nine-Month Financial Results and Operational Highlights
Dow Jones· 2 mins ago
Intelligent Bio Solutions Inc. Reports Fiscal 2024 Third Quarter and Nine-Month Financial Results and Operational Highlights
Year-over-year revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024
Cash and cash equivalents as of March 31, 2024, was $...
Dow Jones· 2 mins ago
Intelligent Bio Solutions Inc. Reports Fiscal 2024 Third Quarter and Nine-Month Financial Results and Operational Highlights
Year-over-year revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024
Cash and cash equivalents as of March 31, 2024, was $...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
TrytosaveabitOP : Intelligent Bio Solutions Inc - Aims to Complete Dosing by End of June 2024